Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
93.06 CHF | +1.67% | +1.43% | +10.04% |
31/05 | NOVARTIS AG : UBS reiterates its Buy rating | ZD |
31/05 | European Equities Close Higher in Friday Trading; Flash Euro Area Inflation Rises More Than Expected | MT |
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company's enterprise value to sales, at 4.12 times its current sales, is high.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+10.04% | 21TCr | - | ||
+40.73% | 74TCr | C+ | ||
+32.83% | 60TCr | B | ||
-6.30% | 35TCr | C+ | ||
+15.15% | 32TCr | B- | ||
+4.05% | 28TCr | C+ | ||
+15.00% | 24TCr | B+ | ||
-5.52% | 21TCr | A+ | ||
+6.17% | 16TCr | C+ | ||
-0.45% | 16TCr | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- NOVN Stock
- NOVNEE Stock
- Ratings Novartis AG